

Thiago Vidotto, MSc, PhD

xxxxxxxxx@gmail.com | +55xxxxxxxxx

LinkedIn: <https://www.linkedin.com/in/thiago-vidotto-17939784>

EDUCATION

Post-doctoral fellow in Pathology (June 2019 - July 2020)

- Johns Hopkins Hospital, Baltimore, USA.

PhD in Genetics (September 2015 - March 2019)

- University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
- Queen's University, Kingston, Canada (Sandwich PhD for 8 months)

MSc in Psychobiology (January 2013 - September 2015)

- University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

BSc in Life Sciences (January 2009 - January 2012)

- State University of Londrina, Londrina, Paraná, Brazil.

RESEARCH EXPERIENCE

Post-doctoral fellow – Johns Hopkins Hospital, Baltimore, USA (June 2019 – July 2020)

- Analyzed and integrated genomic methylation data of 3 independent prostate cancer cohorts to determine disease outcome and to identify clinical markers of progression.
- Integrated gene expression, mutational, and methylation data using clustering pipelines.
- Measured the impact of genomic alterations in the immune response from 290 Black and White patients with prostate cancer disease.
- Generated immune-cell density data from methylation and gene expression platforms.
- Validated Gleason Score classification pipelines generated with Artificial Intelligence.
- Analysed RNAseq data from tumor samples and cell lines to identify differentially expressed genes and enriched pathways.
- Obtained percent genome altered and other genomic parameters from methylation data.
- Published 5 high-impact papers derived from this research.

PhD Sandwich – Cancer Research Institute, Queen's University, Kingston, Canada (December 2017 – August 2018)

- Analysed RNAseq, WGS, WES, and clinical data from public domain and Canadian consortium databases.
- Employed bioinformatics tools to evidence the association between mutations in bladder tumors and tumor microenvironment changes.
- Analysed the effect of mutations and genomic rearrangements on the expression of immune-cell markers and activators.
- Experience in bioinformatics and biostatistics using R programming language.

PhD in Genetics – University of São Paulo, São Paulo, Brazil (September 2015 – March 2019)

- Integrated pathological, genomic, and clinical data obtained from immunohistochemistry, array-CGH, sequencing, and FISH experiments of prostate cancer and glioblastoma.
- Employed bioinformatics and statistical tools to elucidate the mechanisms of inactivation of PTEN and its impacts in the genome and immune response of prostate cancer disease.
- Published 4 high-impact papers derived from this research.

PUBLICATIONS IN PEER-REVIEWED JOURNALS

WEINER, A B; **VIDOTTO, T** et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. **Nature Communications**, v. 12, p. 935, 2021.

CHENARD, S; JACKSON, C; **VIDOTTO, T** et al. Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint. **European Urology Open Science**, v. 29, p. 50-58, 2021.

ASRANI, K; TORRES, A F C; WOO, J; **VIDOTTO, T** et al. Reciprocal YAP1 loss and expression in neuroendocrine prostate cancer. **Journal of Pathology**, in press, 2021.

IMADA, E L; SANCHEZ, D F; DINALANKARA, W; **VIDOTTO, T** et al. Transcriptional landscape of PTEN loss in primary prostate cancer. **BMC Cancer**, v. 21, p. 856-864, 2021.

SALLES, D C; **VIDOTTO, T** et al. (joint first-author) Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies. **Journal of Molecular Diagnostics**, v. 23, p. 1030-1041, 2021.

JAMASPISHVILI, T; PATEL, P G; NIU, Y; **VIDOTTO, T** et al. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). **Journal of the National Cancer Institute**, v. 112, p. 1098-1104, 2020.

VIDOTTO, T et al. Emerging role of PTEN loss in evasion of the immune response to tumours. **British Journal of Cancer**, v. 122, p. 1732-1743, 2020.

HARMON, S A; PATEL, P G; SANFORD, T H.; CAVEN, I; ISEMAN, R; **VIDOTTO, T** et al. High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. **Modern Pathology**, v. 34, p. 478-489, 2020.

VIDOTTO, T et al. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. **The Prostate**, v. 79, p. 969-979, 2019.

VIDOTTO, T et al. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes. **Journal for Immunotherapy of Cancer**, v. 7, p. 148-156, 2019.

VIDOTTO, T et al. Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. **Molecular Cytogenetics**, v. 11, p. 1-9, 2018.

And 10 more publications in high-impact journals in the field of oncology, pathology, and bioinformatics.

LANGUAGE

English (fluent), Spanish (basic), Portuguese (native speaker).

SOFT SKILLS

Managed and led an innovative teaching experience for 4000 Brazilian students through on-line courses.

Developed and led a team of 20 manuscript editors from Australia, Brazil, United Kingdom, Canada, and United States.